新型冠状病毒肺炎疫情防控常态化阶段的异基因造血干细胞移植  

Allogeneic hematopoietic stem cell transplantation during the normalization stage of COVID-19 management

作　　者：刘启发[1] 林韧[1] Liu Qifa;Lin Ren(Department of Hematology,Nanfang Hospital,Southern Medical University,Clinical Medical Research Center of Hematological Diseases of Guangdong Province,Guangzhou 510515,China)

机构地区：[1]南方医科大学南方医院血液科,南方医科大学血液病研究所,广东省血液系统疾病临床医学研究中心,广州510515

出　　处：《中华血液学杂志》2024年第11期977-981,共5页Chinese Journal of Hematology

基　　金：国家自然科学基金(82070190、81970161)。

摘　　要：目前全球已经进入新型冠状病毒肺炎(COVID-19)疫情防控常态化阶段。COVID-19仍将在较长时间内影响异基因造血干细胞移植(allo-HSCT)患者,作者探讨现阶段COVID-19对allo-HSCT策略及预后的可能影响。移植前感染SARS-CoV-2的患者移植时机选择在症状缓解且SARS-CoV-2转阴后为优。供者采集时感染或并不影响采集。allo-HSCT患者移植早期发生COVID-19仍有较高的重症发生率;重症COVID-19仍然是移植后非复发死亡和生存的危险因素。COVID-19与移植后并发症如其他感染、内皮损伤相关并发症及复发的关系有待进一步大样本研究。At present,the world has entered the normalization stage of coronavirus disease 2019(COVID-19)management.COVID-19 continues to affect patients with allogeneic hematopoietic stem cell transplantation(allo-HSCT)for a long period.The author discussed the possible effect of COVID-19 on HSCT strategy and prognosis during this period based on literature reports.Transplantation should be deferred until clinical resolution and negative severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)in patients infected with SARS-CoV-2 before transplantation.Donors infected with SARS-CoV-2 during the stem cell collection may not affect apheresis.Allo-HSCT recipients demonstrated a high rate of severe COVID-19 if COVID-19 occurred at the early stage of transplantation.Severe COVID-19 remains a risk factor for nonrelapse mortality and survival after transplantation.The association between COVID-19 and post-transplantation complications,such as other infections,endothelial injury-related complications,and relapse,needs to be further investigated in large samples.

关 键 词：疫情防控 新型冠状病毒 内皮损伤 异基因造血干细胞移植 相关并发症 大样本研究 危险因素 常态化 

分 类 号：R457.7[医药卫生—治疗学]